55 results on '"Engert, Andreas"'
Search Results
2. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
3. Neue Ansätze zur Behandlung des rezidivierten oder refraktären Hodgkin Lymphoms
4. Therapiealgorithmus für Patienten mit Hodgkin-Lymphom
5. Behandlung des nodulär Lymphozyten-prädominanten Hodgkin Lymphoms
6. Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma
7. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis
8. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
9. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
10. Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
11. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma
12. Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
13. Evidenzbasierte Erstlinientherapie des Hodgkin-Lymphoms
14. Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
15. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
16. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation
17. Rezidiviertes oder refraktäres klassisches Hodgkin-Lymphom
18. Therapiealgorithmus für Patienten mit Hodgkin-Lymphom
19. Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude
20. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci
21. The GHSG Approach to Treating Hodgkin’s Lymphoma
22. Heritability estimates on Hodgkin’s lymphoma: a genomic- versus population-based approach
23. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma
24. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
25. Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin’s lymphoma
26. Phase II sudy of cetuximab for the treatment of refractory or relapsed multiple myeloma Erbitux for Multiple MyelomA
27. A randomised trial of BEAM plus peripheral blood stem cell transplantion (PBSCT) versus single agent high-dose therapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease
28. Advances in the treatment of Hodgkin lymphoma
29. State of the art in the treatment of Hodgkin lymphoma
30. Hodgkin lymphoma—absence of evidence not evidence of absence!
31. The Role of Autologous Transplantation in Hodgkin Lymphoma
32. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)
33. Transnational Hedge Fund Regulation
34. How Does the Market React to the Societas Europaea?
35. Incorporating under European Law: The Societas Europaea as a Vehicle for Legal Arbitrage
36. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
37. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab
38. Nodular lymphocyte-predominant Hodgkin lymphoma
39. Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies
40. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
41. Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin???s Lymphoma and its Effect on Myelotoxicity
42. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma
43. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
44. Cancer-related anemia and recombinant human erythropoietin—an updated overview
45. First-line treatment of Hodgkin’s lymphoma
46. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma
47. Axillary swelling and a reduced general condition in a middle-aged man
48. The role of granulopoiesis-stimulating factors in the treatment of malignant lymphoma
49. Recombinant Human Erythropoietin as an Alternative to Blood Transfusion in Cancer-Related Anaemia
50. Antiangiogenese: ein neuer Ansatz in der Tumortherapie?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.